ClinicalTrials.gg
CompletedNCT00113763Updated Nov 7, 2022Results posted

Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of Best supportive care and Panitumumab in Colorectal Cancer and Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2004, registered Jun 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
10th of 88
463 · median 70
Started
2004
with 3 others
Phase 3
14 of 90
2 open now
Registered
7th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 10th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2004, is one of 14 in phase 3, and was the 7th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).

03

Conditions studied

  • Colorectal Cancer
  • Metastases

Keywords

  • Metastatic Colorectal Cancer, Colon
  • Colorectal, Rectal Cancer, Cancer
  • Metastatic, EGFr, Clinical Trial
  • Panitumumab, ABX-EGF
  • Immunex, Abgenix, Amgen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue )
  • colorectal carcinoma
  • (ECOG) performance status of 0, 1 or 2
  • Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer
  • Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen
  • Unidimensionally
  • Tumor expressing epidermal growth factor receptor (EGFr) by immunohistochemistry
  • At least 2 but not more than 3 prior chemotherapy regimens for colorectal cancer
  • Adequate hematologic, renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Symptomatic requiring treatment
  • History or evidence of interstitial pneumonitis or pulmonary fibrosis
  • Use of systemic chemotherapy or radiotherapy within 30 days prior to enrollment
  • Prior epidermal growth factor receptor (EGFr) targeting therapies
  • Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than a week) serum half life within 30 days before enrollment, or prior experimental or approved proteins within 3 months before enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Panitumumab plus best supportive care

    Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.

    Drug: Panitumumab

  • Other
    Best Supportive Care

    Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.

    Other: Best supportive care

Interventions

  • OtherBest supportive care

    Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).

  • Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.

    Also known as: ABX-EGF

06

What researchers measure

Primary outcomes

  1. Progression-free Survival Time

    Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression, whichever occurred first. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.

    Time frame: From randomization to the data cut-off date of 30 June 2005. The median follow-up time was 20.0 weeks in the panitumumab plus BSC group and 18.2 weeks in the BSC alone group.

Secondary outcomes

  1. Overall Survival

    Kaplan-Meier estimates of median time from randomization to death.

    Time frame: From randomization until the data cut-off date for overall survival of 15 March 2006. The median actual follow-up time was 30 weeks for the panitumumab plus BSC group and 31 weeks for the BSC alone group.

  2. Objective Tumor Response

    Defined as the number of participants with a confirmed complete or partial tumor response, confirmed by a scan no less than 4 weeks after the criteria for response were first met. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): disappearance of all target lesions, and persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, with no progressive disease of non-target lesions.

    Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.

  3. Duration of Response

    Kaplan-Meier estimate of the median time from first confirmed objective tumor response to first observed progression of disease or death due to progression of disease (whichever comes first).

    Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.

  4. Time to Response

    Time to response was defined as the time from randomization to first partial or complete response, subsequently confirmed ≥ 4 weeks after the criteria for response were first met.

    Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.

  5. Time to Disease Progression

    Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)

    Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.

  6. Time to Treatment Failure

    Kaplan-Meier estimate of the median time from randomization to the date the decision was made to end treatment for any reason.

    Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.

  7. Duration of Stable Disease

    Kaplan-Meier estimate of the median time from randomization to date of first observed progression of disease or death due to progression of disease (whichever comes first) for those participants with a best response of stable disease. Stable disease defined as neither sufficient shrinkage to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir longest diameter since the treatment started, no unequivocal progression of existing non-target lesions, and no new lesions.

    Time frame: From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.

07

Results

Posted Jan 3, 2014

Participant flow

Participants were enrolled from 16 January 2004 through 16 March 2005. Data are up until the data cutoff of 15 March 2007.

Participant flow — Overall Study
MilestonePanitumumab Plus BSCBSC Alone
Started231232
Received study drug2290
Completed158206
Not completed7326
Withdrew: Adverse event52
Withdrew: Disease progression2814
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject14
Withdrew: Other276
Withdrew: Non-compliance10
Withdrew: Ongoing10

Outcome measures

PrimaryProgression-free Survival Time

Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression, whichever occurred first. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.

Time frame:
From randomization to the data cut-off date of 30 June 2005. The median follow-up time was 20.0 weeks in the panitumumab plus BSC group and 18.2 weeks in the BSC alone group.
Reported as:
Median · weeks
Progression-free Survival Time
weeksPanitumumab Plus BSCBSC Alone
Progression-free Survival Time8.0 (7.9 to 8.4)7.3 (7.1 to 7.7)
Statistical analysis
  • Panitumumab Plus BSC vs BSC Alone · Log Rank · p = <0.0001Stratified by baseline IVRS ECOG performance status and geographic region
SecondaryOverall Survival

Kaplan-Meier estimates of median time from randomization to death.

Time frame:
From randomization until the data cut-off date for overall survival of 15 March 2006. The median actual follow-up time was 30 weeks for the panitumumab plus BSC group and 31 weeks for the BSC alone group.
Reported as:
Median · months
Overall Survival
monthsPanitumumab Plus BSCBSC Alone
Overall Survival6.4 (6.1 to 7.7)6.3 (4.9 to 7.6)
Statistical analysis
  • Panitumumab Plus BSC vs BSC Alone · Log Rank · p = 0.806 (This analysis was conducted contingent on a statistically significant difference in the primary outcome, and adjusted to an a priori threshold for statistical significance at a 4% level for a multiple comparison involving objective tumor response)Stratified by baseline IVRS ECOG performance status and geographic region
SecondaryObjective Tumor Response

Defined as the number of participants with a confirmed complete or partial tumor response, confirmed by a scan no less than 4 weeks after the criteria for response were first met. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): disappearance of all target lesions, and persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, with no progressive disease of non-target lesions.

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Reported as:
Number · participants
Objective Tumor Response
participantsPanitumumab Plus BSCBSC Alone
Objective Tumor Response220
SecondaryDuration of Response

Kaplan-Meier estimate of the median time from first confirmed objective tumor response to first observed progression of disease or death due to progression of disease (whichever comes first).

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Reported as:
Median · weeks
Duration of Response
weeksPanitumumab Plus BSCBSC Alone
Duration of Response18.4 (16.0 to 25.3)—
SecondaryTime to Response

Time to response was defined as the time from randomization to first partial or complete response, subsequently confirmed ≥ 4 weeks after the criteria for response were first met.

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Reported as:
Median · weeks
Time to Response
weeksPanitumumab Plus BSCBSC Alone
Time to Response7.9 (7.3 to 10.6)—
SecondaryTime to Disease Progression

Kaplan-Meier estimates of median time from randomization to disease progression or death due to disease progression (whichever occurs first)

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Reported as:
Median · weeks
Time to Disease Progression
weeksPanitumumab Plus BSCBSC Alone
Time to Disease Progression8.0 (7.9 to 8.9)7.3 (7.1 to 7.7)
SecondaryTime to Treatment Failure

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to end treatment for any reason.

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Reported as:
Median · weeks
Time to Treatment Failure
weeksPanitumumab Plus BSCBSC Alone
Time to Treatment Failure9.0 (8.3 to 12.0)7.1 (6.4 to 7.6)
SecondaryDuration of Stable Disease

Kaplan-Meier estimate of the median time from randomization to date of first observed progression of disease or death due to progression of disease (whichever comes first) for those participants with a best response of stable disease. Stable disease defined as neither sufficient shrinkage to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir longest diameter since the treatment started, no unequivocal progression of existing non-target lesions, and no new lesions.

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.
Reported as:
Median · weeks
Duration of Stable Disease
weeksPanitumumab Plus BSCBSC Alone
Duration of Stable Disease24.0 (22.4 to 27.3)17.6 (15.4 to 25.6)
Post-hocProgression-free Survival Time (Wild-type KRAS)

Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression among participants with wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) status. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time in patients with wild-type KRAS was 36.8 weeks in the panitumumab plus BSC group and 35.7 weeks in the BSC alone group.
Reported as:
Median · weeks
Progression-free Survival Time (Wild-type KRAS)
weeksPanitumumab Plus Best Supportive CareBSC Alone
Progression-free Survival Time (Wild-type KRAS)12.3 (8.3 to 16.1)7.3 (7.0 to 7.7)
Post-hocProgression-free Survival Time (Mutant KRAS)

Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression among participants with mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) status. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.

Time frame:
From randomization until the data cutoff of 15 March 2007. The median follow-up time in patients with mutant KRAS was 24.4 weeks in the panitumumab plus BSC group and 23.9 weeks in the BSC alone group.
Reported as:
Median · weeks
Progression-free Survival Time (Mutant KRAS)
weeksPanitumumab Plus Best Supportive CareBSC Alone
Progression-free Survival Time (Mutant KRAS)7.4 (7.3 to 7.9)7.3 (6.3 to 7.9)

Adverse events

Collected over First dose through maximum of safety FU or 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus BSC—101/229 (44.1%)224/229 (97.8%)
BSC Alone—62/234 (26.5%)171/234 (73.1%)
Most frequent serious events
Showing 10 of 146
Most frequent serious events
EventPanitumumab Plus BSCBSC Alone
COLORECTAL CANCER METASTATICNeoplasms benign, malignant and unspecified (incl cysts and polyps)30/22924/234
COLORECTAL CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)16/2299/234
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders14/2296/234
INTESTINAL OBSTRUCTIONGastrointestinal disorders11/2294/234
ABDOMINAL PAINGastrointestinal disorders8/2298/234
PYREXIAGeneral disorders1/2298/234
CONSTIPATIONGastrointestinal disorders7/2290/234
DYSPNOEARespiratory, thoracic and mediastinal disorders6/2294/234
HEPATIC FAILUREHepatobiliary disorders5/2294/234
VOMITINGGastrointestinal disorders4/2295/234
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPanitumumab Plus BSCBSC Alone
ERYTHEMASkin and subcutaneous tissue disorders150/2292/234
PRURITUSSkin and subcutaneous tissue disorders132/2294/234
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders131/2292/234
ANOREXIAMetabolism and nutrition disorders63/22944/234
FATIGUEGeneral disorders59/22934/234
PARONYCHIAInfections and infestations57/2290/234
ABDOMINAL PAINGastrointestinal disorders56/22936/234
NAUSEAGastrointestinal disorders51/22935/234
RASHSkin and subcutaneous tissue disorders51/2292/234
DIARRHOEAGastrointestinal disorders48/22926/234

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab Plus BSCBSC AloneTotal
Mean61.2 ± 10.361.4 ± 10.861.3 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus BSCBSC AloneTotal
Female8584169
Male146148294
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab Plus BSCBSC AloneTotal
Japanese011
Aborigine000
Other000
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American101
White or Caucasian229228457
Hispanic or Latino112
Region of Enrollment
Region of Enrollment(participants)Panitumumab Plus BSCBSC AloneTotal
Central and Eastern Europe201939
Western Europe178180358
Rest of World333366
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)Panitumumab Plus BSCBSC AloneTotal
0 or 1200202402
2313061
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bai JP, Bell R, Buckman S, Burckart GJ, Eichler HG, Fang KC, Goodsaid FM, Jusko WJ, Lesko LL, Meibohm B, Patterson SD, Puig O, Smerage JB, Snider BJ, Wagner JA, Wang J, Walton MK, Weiner R. Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J. 2011 Jun;13(2):274-83. doi: 10.1208/s12248-011-9265-x. Epub 2011 Mar 30. Erratum In: AAPS J. 2011 Sep;13(3):493. PubMed 21448748 ↗
  • Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011 Feb;26(2):173-81. doi: 10.1007/s00384-010-1112-5. Epub 2010 Dec 29. PubMed 21190026 ↗
  • Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009 Apr 1;115(7):1544-54. doi: 10.1002/cncr.24088. PubMed 19189371 ↗
  • Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007 Dec 3;97(11):1469-74. doi: 10.1038/sj.bjc.6604053. Epub 2007 Nov 27. PubMed 18040272 ↗
  • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 May 1;25(13):1658-64. doi: 10.1200/JCO.2006.08.1620. PubMed 17470858 ↗
  • Liao MZ, Prenen H, Dutta S, Upreti VV. The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. Cancer Chemother Pharmacol. 2021 Oct;88(4):665-672. doi: 10.1007/s00280-021-04319-w. Epub 2021 Jul 2. PubMed 34213592 ↗
  • Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8. PubMed 29627309 ↗
  • Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH, van Krieken JH. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer. 2015 Sep;51(13):1704-13. doi: 10.1016/j.ejca.2015.05.017. Epub 2015 Jun 3. PubMed 26049686 ↗
  • Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol. 2013 Jun;8(2):127-36. doi: 10.1007/s11523-013-0271-z. Epub 2013 Apr 27. PubMed 23625191 ↗
  • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3. PubMed 18316791 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2004 to primary completion in Oct 2008, 57 months.

Results were first posted in Jan 2014, 5 years 3 months after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 57 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2005
First posted
Jun 13, 2005
StartActual
Jan 1, 2004
Primary completionActual
Oct 1, 2008
CompletionActual
Jun 1, 2009
Results first posted
Jan 3, 2014
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00113763
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 13, 2005
Start date
Jan 1, 2004
Primary completion
Oct 1, 2008
Completion
Jun 1, 2009
Results posted
Jan 3, 2014
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion